Skip to main content

Table 4 Univariate analysis (unadjusted relative risks) for disease-free and overall survival

From: Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse

  DFS Overall survival
  HR 95% CI P-value HR 95% CI P-value
Menopausal status   1.075 to 3.064    1.027 to 3.836  
Post vs Pre 1.815   0.026 1.985   0.041
Tumor status   1.304 to 4.419    1.710 to 11.114  
T2/T3 vs T1 2.401   0.005 4.359   0.002
Nodes   1.418 to 3.832    1.527 to 5.207  
N> 3 vs N0-3 2.331   0.001 2.819   0.001
Histology grade   0.989 to 2.805    0.644 to 2.390  
3 vs 1/2 1.665   0.055 1.240   0.520
HR   0.454 to 1.504    0.585 to 2.387  
ER(-)/PR(-) vs other 0.826   0.533 1.182   0.641
Triple negative   0.454 to 1.681    0.492 to 2.348  
ER(-)/PR(-)/HER-2 vs Other 0.874   0.686 1.075   0.856
Hormonotherapy   0.696 to 3.759    0.442 to 4.687  
No vs Yes 1.618   0.264 1.439   0.546
Chemotherapy CMF (ref)   0.589 to 3.812    0.352 to 2.976
FEC    0.339    0.911
T/EC 1.498 0.389 to 2.745 0.396 1.024 0.388 to 3.564 0.966
  1.034   0.947 1.176   0.775
CK-19 at five years FU
Persistently negative
Turn to negative
Turn to positive
Persistently positive (ref)
0.300
0.201
0.498
0.144 to 0.623
0.079 to 0.513
0.264 to 0.939
0.001
0.001
0.031
< 0.001
0.318
0.260
0.582
0.121 to 0.836
0.078 to 0.868
0.271 to 1.253
0.020
0.028
0.167
0.025
  1. CK-19, cytokeratine-19; CMF, Cyclophosphamide-Methotraxate-Fluorouracil; DFS, disease-free survival; FEC, Fluorouracil-Epirubicin-Cyclophosphamide; HR, hormone receptor; T/EC, Taxane/Epirubicin-Cyclophosphamide.